Sign in Subscribe
United States. Securities and Exchange Commission

Sciclone Pharmaceuticals Inc. Files SEC Form SC 13D

Strategic Insights

— 1 min read

Sciclone Pharmaceuticals Inc., a pharmaceutical preparation company, has submitted a Form SC 13D filing with the U.S. Securities and Exchange Commission on August 21, 2015. This filing discloses beneficial ownership of certain registered equity securities by individuals or groups of persons who have acquired a stake of more than 5% in the company. The document was filed under the SEC file number 0001144204-15-051156, and the company's contact information is listed as 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125, with a phone number of 650-358-3456.

Key Takeaways:

  • Sciclone Pharmaceuticals Inc. filed a Form SC 13D with the SEC on August 21, 2015, disclosing beneficial ownership of registered equity securities.
  • The company's SIC code is 2834, indicating pharmaceutical preparations.
  • The filing is subject to the SEC's rules defining "beneficial owner" as any person who directly or indirectly shares voting power or investment power.
  • Sciclone Pharmaceuticals Inc. must file amendments to Schedule 13D if there are material changes in the facts reported.
  • The company's filing is available on the SEC's website at http://www.sec.gov/Archives/edgar/data/1562291/0001144204-15-051156-index.html.

Statistics:

  • Date of SEC filing: August 21, 2015
  • SEC file number: 0001144204-15-051156
  • Company SIC code: 2834
  • Contact information: 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125, 650-358-3456

Sources:

  • News newspaper, 2015 SEP 7
  • "Pharmaceutical preparations" category, NewsRx
  • U.S. Securities and Exchange Commission website, http://www.sec.gov/Archives/edgar/data/1562291/0001144204-15-051156-index.html
  • Sciclone Pharmaceuticals Inc. SEC filing, Form SC 13D, 0001144204-15-051156

Read more